Prognosis and management of polymyalgia rheumatica

Polymyalgia rheumatica (PMR) is commonly found in Northern Europe and in persons of Scandinavian extraction in the US, with an annual incidence of around 50 per 100,000 population over 50 years of age, in whom it should be considered in the differential diagnosis of musculoskeletal disorde...

Full description

Bibliographic Details
Main Author: Diana Samara
Format: Article
Language:English
Published: Faculty of Medicine Trisakti University 2011-04-01
Series:Universa Medicina
Subjects:
Online Access:http://www.univmed.org/wp-content/uploads/2011/04/diana.pdf
_version_ 1828955006980587520
author Diana Samara
author_facet Diana Samara
author_sort Diana Samara
collection DOAJ
description Polymyalgia rheumatica (PMR) is commonly found in Northern Europe and in persons of Scandinavian extraction in the US, with an annual incidence of around 50 per 100,000 population over 50 years of age, in whom it should be considered in the differential diagnosis of musculoskeletal disorders. The disorder is twice more common in women than in men. PMR is closely related to giant cell arteritis and both disorders are considered to have a common pathogenesis, associated with genetic and environmental factors (viral and bacterial infections). There is no gold diagnostic standard for PMR and the diagnosis rests on a high index of suspicion in persons older than 50 years with musculoskeletal symptoms. As an aid in diagnosis, several sets of diagnostic criteria have been used, usually related to age at onset, duration, symptoms, inflammatory markers, and response to corticosteroids. Patients with PMR usually present with acute onset of stiffness and pain in the shoulder and pelvic musculature, which may be accompanied by fever, malaise, and weight loss. The symptoms of PMR seem to be related to synovitis of proximal joints and extra-articular synovial structures. PMR may occur as an isolated syndrome or accompany other diseases, mainly giant cell arteritis. It usually responds quickly to once-daily, low-dose prednisone, but some patients require treatment for several years. Monitoring for corticosteroid-associated side effects such as osteoporosis and diabetes, as well as for relapses and flare-ups, is key to chronic management.
first_indexed 2024-12-14T07:41:56Z
format Article
id doaj.art-f53bcd1b65d349ba8d118033db6acee0
institution Directory Open Access Journal
issn 1907-3062
language English
last_indexed 2024-12-14T07:41:56Z
publishDate 2011-04-01
publisher Faculty of Medicine Trisakti University
record_format Article
series Universa Medicina
spelling doaj.art-f53bcd1b65d349ba8d118033db6acee02022-12-21T23:11:01ZengFaculty of Medicine Trisakti UniversityUniversa Medicina1907-30622011-04-013016370Prognosis and management of polymyalgia rheumaticaDiana Samara0Department of Anatomy Medical Faculty, Trisakti UniversityPolymyalgia rheumatica (PMR) is commonly found in Northern Europe and in persons of Scandinavian extraction in the US, with an annual incidence of around 50 per 100,000 population over 50 years of age, in whom it should be considered in the differential diagnosis of musculoskeletal disorders. The disorder is twice more common in women than in men. PMR is closely related to giant cell arteritis and both disorders are considered to have a common pathogenesis, associated with genetic and environmental factors (viral and bacterial infections). There is no gold diagnostic standard for PMR and the diagnosis rests on a high index of suspicion in persons older than 50 years with musculoskeletal symptoms. As an aid in diagnosis, several sets of diagnostic criteria have been used, usually related to age at onset, duration, symptoms, inflammatory markers, and response to corticosteroids. Patients with PMR usually present with acute onset of stiffness and pain in the shoulder and pelvic musculature, which may be accompanied by fever, malaise, and weight loss. The symptoms of PMR seem to be related to synovitis of proximal joints and extra-articular synovial structures. PMR may occur as an isolated syndrome or accompany other diseases, mainly giant cell arteritis. It usually responds quickly to once-daily, low-dose prednisone, but some patients require treatment for several years. Monitoring for corticosteroid-associated side effects such as osteoporosis and diabetes, as well as for relapses and flare-ups, is key to chronic management.http://www.univmed.org/wp-content/uploads/2011/04/diana.pdfPainstiffnesspolymyalgia rheumaticacorticosteroids
spellingShingle Diana Samara
Prognosis and management of polymyalgia rheumatica
Universa Medicina
Pain
stiffness
polymyalgia rheumatica
corticosteroids
title Prognosis and management of polymyalgia rheumatica
title_full Prognosis and management of polymyalgia rheumatica
title_fullStr Prognosis and management of polymyalgia rheumatica
title_full_unstemmed Prognosis and management of polymyalgia rheumatica
title_short Prognosis and management of polymyalgia rheumatica
title_sort prognosis and management of polymyalgia rheumatica
topic Pain
stiffness
polymyalgia rheumatica
corticosteroids
url http://www.univmed.org/wp-content/uploads/2011/04/diana.pdf
work_keys_str_mv AT dianasamara prognosisandmanagementofpolymyalgiarheumatica